Esomeprazol Lek

Esomeprazol Lek is a pharmaceutical product that contains the active ingredient esomeprazole magnesium. It is formulated as an oral dosage form, typically a tablet, and is marketed in the European Union. As a proton pump inhibitor, Esomeprazol Lek works by irreversibly blocking the gastric H+/K+ ATPase enzyme, thereby decreasing gastric acid secretion. The medication is used under medical supervision for conditions related to excess stomach acid.

Esomeprazol Lek is indicated for several acid‑related gastrointestinal disorders where reduction of gastric acidity is required. It is prescribed to promote healing of damaged mucosa and to prevent recurrence of symptoms. - Gastro‑oesophageal reflux disease (GERD) with frequent heartburn or regurgitation. - Healing of erosive oesophagitis confirmed by endoscopy. - Prevention and treatment of NSAID‑induced gastric ulcer. - Management of Zollinger‑Ellison syndrome associated hypersecretion. - Part of combination therapy for Helicobacter pylori eradication.

The safety profile of Esomeprazol Lek includes a range of reported adverse events, most of which are mild, transient, and resolve without specific treatment. Patients should be aware of both common and less frequent serious reactions that may require medical attention.

Common: - Headache, dizziness, or mild fatigue. - Diarrhea, abdominal pain, or flatulence. - Nausea, vomiting, or loss of appetite. - Constipation or dry mouth. - Elevated liver enzymes detected in routine blood tests.

Serious: - Severe allergic reactions such as rash, itching, or swelling. - Clostridioides difficile‑associated colitis presenting with persistent diarrhea. - Low magnesium levels (hypomagnesemia) leading to muscle cramps or irregular heartbeat. - Bone fractures associated with long‑term use.

Before initiating therapy with Esomeprazol Lek, certain precautionary measures and warnings should be considered to ensure safe use. These considerations help identify patients who may need monitoring or alternative treatment. - Assess renal and hepatic function, especially in patients with severe impairment. - Use the lowest effective dose for the shortest duration needed. - Monitor for signs of vitamin B12 deficiency with long‑term therapy. - Evaluate for potential bone density loss in elderly patients. - Consider magnesium level testing if prolonged treatment is planned. - Discontinue or adjust therapy if severe allergic reaction occurs.

Esomeprazol Lek may affect the absorption or metabolism of other medications, making awareness of drug interactions important. Patients should discuss all concurrent medicines with their healthcare provider.

Avoid: - Co‑administration with atazanavir or nelfinavir, which require an acidic environment for absorption. - Use with rilpivirine, as reduced gastric acidity can lower its bioavailability.

Use with caution: - Concomitant use of clopidogrel, where reduced activation may diminish antiplatelet effect. - Combined therapy with warfarin, as altered gastric pH can affect INR monitoring. - Simultaneous use of methotrexate, especially high‑dose regimens, due to potential increased serum levels.